WHAT IS CLAIMED IS:

1. A composition comprising:

(a) a compound of Formula I;

(b) a carboxylic acid, which is citric acid;


(c) sodium phosphate dibasic,

(d) sodium chloride,

(e) a solubilizing agent, and

(f) the remainder water, wherein the pH of the composition is adjusted from about 4 to about 8;

wherein the compound of Formula I has the following structure:



Formula I

wherein:

each of Z_1 to Z_6 is independently C, N, O, or S;

A is $-(CH_2)_6-$, or *cis* $-CH_2CH=CH-(CH_2)_3-$, wherein 1 or 2 carbons may be substituted with S or O; or

A is $-(CH_2)_m-Ar-(CH_2)_o-$ wherein Ar is arylene or heteroarylene, the sum of m and o is from 1 to 4, and wherein one CH_2 may be substituted with S or O;

R_1 is alkyl, cycloalkyl, oxyalkyl, hydroxyalkyl, alkenyl, oxyalkenyl, or hydroxyalkenyl;

R_2 is alkyl, alkenyl, hydroxyl, halide, cyano, or oxo;

J is alkyl, cycloalkyl, oxyalkyl, hydroxyalkyl;

E is C_{1-12} alkyl, R_3, or $-Y-R_3$ wherein Y is CH_2, S, or O, and R_3 is aryl or heteroaryl;

n is 0 or 1;

and wherein a dashed line represents the presence or absence of a bond.

2. The composition of claim 1 having about 0.05 % to about 0.2 % citric acid.

3. The composition of claim 1 having about 0.1 % to about 0.15 % citric acid.

4. The composition of claim 1 having a pH from about 4.5 to about 6.5.

5. The composition of claim 1 having a pH of about 6.0.

6. The composition of claim 1, having about 1.0 % to about 2.0 % sodium phosphate dibasic.


7. The composition of claim 1, having about 1.2 % to about 1.6 % sodium phosphate dibasic.

8. The composition of claim 1 having about 0.05 % to about 0.2 % sodium chloride.


9. The composition of claim 1 having about 0.1 % to about 0.15 % sodium chloride.


10. The composition of claim 1, wherein the solubilizing agent is polysorbate 80 or pluronic F127.

11. A composition comprising:
(a) a compound selected from the group consisting of:



,



and  ;

(b) a carboxylic acid, which is citric acid;

(c) sodium phosphate dibasic;

(d) sodium chloride;

(e) a solubilizing agent; and

(f) the remainder water, wherein the pH of the composition is adjusted from about 4 to about 8.

12. The composition of claim 11 having about 0.05 % to about 0.2 % citric acid.

13. The composition of claim 11 having about 0.1 % to about 0.15 % citric acid.

14. The composition of claim 11 having a pH from about 4.5 to about 6.5.

15. The composition of claim 11 having a pH of about 6.0.

16. The composition of claim 11, having about 1.0 % to about 2.0 % sodium phosphate dibasic.

17. The composition of claim 11, having about 1.2 % to about 1.6 % sodium phosphate dibasic.

18. The composition of claim 11 having about 0.05 % to about 0.2 % sodium chloride.

19. The composition of claim 11 having about 0.1 % to about 0.15 % sodium chloride.

20. The composition of claim 11, wherein the solubilizing agent is polysorbate 80 or pluronic F127.

21. Use of a composition according to claim 1 in the manufacture of a medicament for the treatment of an ocular disorder.

22. The use of claim 21 wherein the disorder is glaucoma, elevated intraocular pressure, optic neuropathy, corneal pain, diabetic retinopathy, retinal dystrophies, macular degeneration, non-exudative age related macular degeneration (ARMD), exudative Age Related Macular Degeneration (ARMD), Lebers optic neuropathy, optic neuritis often associated with multiple sclerosis, retinal vein occlusions, ischemic neuropathies and other neurodegenerative diseases, choroidal neovascularization, central serous chorioretinopathy, cystoid macular edema, diabetic macular edema, myopic retinal degeneration, acute multifocal placoid pigment epitheliopathy, Behcet's disease, birdshot retinochoroidopathy, intermediate uveitis (pars planitis), multifocal choroiditis, multiple evanescent white dot syndrome (MEWDS), ocular sarcoidosis, posterior scleritis, serpiginous choroiditis, subretinal fibrosis and uveitis syndrome, Vogt-Koyanagi-Harada syndrome, punctate inner choroidopathy, acute posterior multifocal placoid pigment epitheliopathy, acute retinal pigment epitheliitis, acute macular neuroretinopathy, and following procedures such as photodynamic therapy and laser-assisted *in situ* keratomileusis (LASIK).

23. The use of claim 21 wherein the disorder is glaucoma or elevated intraocular pressure.

WHAT IS CLAIMED IS:

1. A composition comprising an ester of a prostanoid agonist, a carboxylic acid, about 1.2 wt% to about 1.6 wt% sodium phosphate dibasic, sodium chloride, a solubilizing agent, and the remainder water, wherein the pH of the composition is from about 4 to about 8.


2. The composition of claim 1, wherein the carboxylic acid is a C_1 to C_{10} carboxylic acid.

3. The composition of claim 1, wherein the carboxylic acid is citric acid.

4. The composition of claim 1, which comprises about 0.05 wt% to about 0.2 wt%, preferably about 0.1 wt% to about 0.15 wt% and more preferably 0.135 wt%, carboxylic acid.

5. The composition of claim 1, having a pH from about 4.5 to about 6.5, preferably about 6.0.

6. The composition of claim 1, wherein the ester of a prostanoid agonist has the structure:



wherein:

each of Z_1 to Z_6 is independently C, N, O, or S;

A is $-(CH_2)_6-$ or *cis* $-CH_2CH=CH-(CH_2)_3-$, wherein 1 or 2 carbons may be substituted with S or O; or

A is $-(CH_2)_m-Ar-(CH_2)_o-$, wherein Ar is arylene or heteroarylene, the sum of m and o is from 1 to 4, and wherein one CH_2 may be substituted with S or O;

R_1 is alkyl, cycloalkyl, oxyalkyl, hydroxyalkyl, alkenyl, oxyalkenyl, or hydroxyalkenyl;

R_2 is alkyl, alkenyl, hydroxyl, halide, cyano, or oxo;

J is alkyl, cycloalkyl, oxyalkyl, hydroxyalkyl;

E is C_{1-12} alkyl, R_3 or -Y-R_3 wherein Y is CH_2, S or O, and R_3 is aryl or heteroaryl;

n is 0 or 1; and


a dashed line represents the presence or absence of a bond.


7. The composition of claim 6, wherein n is 0.


8. The composition of claim 6, wherein R_1 is alkyl or hydroxyalkyl.

9. The composition of claim 6, wherein R_1 is isopropyl or -CH_2-CH_2-OH.

10. The composition of claim 6, wherein the ester of a prostanoid agonist is one of the following compounds:







11. The composition of claim 1, which comprises about 1.42 wt% sodium phosphate dibasic.

12. The composition of claim 1 which comprises about 0.05 wt% to about 0.2 wt%, preferably about 0.1 wt% to about 0.15 wt% and more preferably 0.135 wt%, sodium chloride.

13. The composition of claim 1, wherein the solubilizing agent is polysorbate 80 or pluronic F127.

14. A composition according to claim 1 for use in a method for treating an ocular disorder.

15. A composition for use according to claim 14, wherein the ocular disorder is selected from glaucoma, elevated intraocular pressure, optic neuropathy, corneal pain, diabetic retinopathy, retinal dystrophies, macular degeneration, non-exudative age related macular degeneration (ARMD), exudative Age Related Macular Degeneration (ARMD), Lebers optic neuropathy, optic neuritis often associated with multiple sclerosis, retinal vein occlusions, ischemic neuropathies and other neurodegenerative diseases, choroidal neovascularization, central serous chorioretinopathy, cystoid macular edema, diabetic macular edema, myopic retinal degeneration, acute multifocal placoid pigment epitheliopathy, Behcet's disease, birdshot retinochoroidopathy, intermediate uveitis (pars planitis), multifocal choroiditis, multiple evanescent white dot syndrome (MEWDS), ocular sarcoidosis, posterior scleritis, serpiginous choroiditis, subretinal fibrosis and uveitis syndrome, Vogt-Koyanagi-Harada syndrome, punctate inner choroidopathy, acute posterior multifocal placoid pigment epitheliopathy, acute retinal pigment epitheliitis, acute macular neuroretinopathy and disorders caused by a procedure such as photodynamic therapy or

laser-assisted *in situ* keratomileusis (LASIK), and the disorder is preferably glaucoma or elevated intraocular pressure.